19 results about "Targeted immunotherapy" patented technology

The invention provides an immunotherapy reaction marker identification method and system based on a cooperative game theory, and relates to the technical field of intelligent medical treatment, and the method comprises the following steps: obtaining immunotherapy single cell sequencing data, and determining a candidate gene set through differential expression analysis; extracting regulation and control relation pairs of the candidate gene set to obtain a multi-level information gene regulation and control network; embedding the multilevel information gene regulation and control network by adopting a Node2vec algorithm to obtain a network module containing potential biological functions, calculating the contribution degree of each gene feature to model prediction based on a Myerson value, and obtaining a feature importance sequence; combining the optimal features of the modules into a global candidate set; and iteratively optimizing the global candidate set, and outputting a target immunotherapy reaction marker set. Through a Myerson value principle in a cooperative game, a biomarker set related to immunotherapy response is efficiently searched, deep analysis of a drug resistance mechanism is realized, the accuracy and robustness of marker screening are improved, and the method serves for cancer clinical scheme customization.

Methods and compounds for conferring kidney-glomerular-specific immunotherapy.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

Relapsed / refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target / off-tumor toxicity. The present invention provides CD1a-targeting moieties comprising a CD1a-which may be placed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides a virus like particle comprising a viral structural protein and a galectin epitope peptide, and a composition or vaccine comprising thereof, its use in a medicine, particularly in an immunotherapy.

The invention discloses a chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation as well as a preparation method and application of the chemical crosslinking type bacterial outer membrane vesicle-PD-L1 composite nano preparation. According to the nano preparation, outer membrane vesicles derived from fecal bacillus rodent are taken as a delivery carrier, and an anti-PD-L1 antibody is stably coupled to the surfaces of the vesicles under the chemical cross-linking action of DSPE-PEG-NHS, so that the composite nano preparation MVs / alpha-PD-L1 is formed; in-vitro experiments show that the composite nano preparation can significantly inhibit the activity of breast cancer cells and induce apoptosis of the breast cancer cells; in a 4T1 in-situ breast cancer mouse model, tumor growth can be effectively inhibited, a tumor immune microenvironment can be remodeled, the biological safety is good, and a safe and effective novel delivery system is provided for targeted immunotherapy of breast cancer.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

The invention provides application of luteolin in enhancement of lung cancer targeted immunotherapy, relates to the technical field of biological medicine, and relates to combined application of traditional Chinese medicine monomer luteolin and an immunotherapy preparation of a targeted immune checkpoint B7-H3 in treatment of non-small cell lung cancer (NSCLC). The immunotherapeutic agent is preferably a bispecific killer cell adapter (BiKE) that targets both B7-H3 and CD16. In-vitro cell experiments and in-vivo animal models prove that luteolin can significantly enhance the killing effect of the B7-H3 targeted immunotherapy on NSCLC cells, and the luteolin and the B7-H3 targeted immunotherapy show a significant synergistic anti-tumor effect. The action mechanism of the luteolin is possibly related to the luteolin for inducing cell apoptosis, improving the level of reactive oxygen species (ROS) in cells and inhibiting a PI3K / AKT signal channel. The combined strategy provides a new effective scheme for solving the problems of limited curative effect and drug resistance of NSCLC immunotherapy, and has a good clinical application prospect.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory discase, and immunodeficiency, or condition associated therewith.

This invention provides a BiTE for targeted immunotherapy of tumors, its preparation method, and its application, relating to the field of biopharmaceutical technology. The BiTE is obtained by conjugating a nanobody to a fusion protein. The nanobody contains the amino acid sequence SEQ ID No. 3 at its C-terminus and has the function of targeting the human epidermal growth factor receptor on tumor cells. The fusion protein also targets the CD3 receptor on T cells and activates T cells, connecting T cells and tumor cells in time and space, activating T cells to secrete perforin and granzyme B to kill tumor cells, thus exerting a targeted immunotherapy effect. This invention utilizes isopeptide bonds to conjugate the nanobody and the fusion protein, completing the conjugation within 15 minutes with a conjugation efficiency of 100%, and extending the in vivo half-life of the nanobody by 6 times.

The invention discloses a curative effect prediction method for a hepatocellular carcinoma patient receiving TACE combined target immunotherapy, and relates to the field of medical data processing, and the method comprises the steps: inputting energy spectrum CT data and perfusion CT data into a first deep learning model, predicting a first curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the first deep learning model; inputting the image data into a second deep learning model, and predicting a second curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the second deep learning model; inputting the clinical examination data into a third deep learning model, and predicting a third curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy through the third deep learning model; and performing cross-modal fusion on the first curative effect prediction result, the second curative effect prediction result and the third curative effect prediction result to obtain a target curative effect prediction result of the target hepatocellular carcinoma patient receiving the TACE combined target immunotherapy.

The invention belongs to the technical field of biotechnology and immunology, and particularly relates to application of MTAP as a tumor immunosuppression state and prognosis marker and as a tumor immunotherapy target. The invention reveals that MTAP does not have a'cancer inhibition 'function in TAMs for the first time, but promotes immune escape by inhibiting ferroptosis, breaks through the traditional cognition on the MTAP function, provides a scientific basis for developing a tumor prognosis detection method based on MTAP, an immunosuppressive cell transformation strategy and a novel TAMs-targeted immunotherapy strategy, and has a wide application prospect. A new path is provided for improving the solid tumor immunotherapy curative effect and overcoming drug resistance. The invention also provides an application of the MTAP as a marker in preparation of a detection reagent for predicting the immunosuppression state or clinical prognosis of a tumor patient and an application of the MTAP as an immunotherapy target in preparation of a tumor immunotherapy drug, so that a new thought is provided for tumor detection and immunotherapy.

Disclosed are engineered cells comprising chimeric antigen receptors and uses thereof for treating prostate cancer.

Relapsed / refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor T-cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CARTs fratricide. CD1a is exclusively expressed in cortical T-ALLs, a major subset of T-ALL. The expression of CD1a is restricted to cortical thymocytes and neither CD34+ progenitors nor T-cells express CD1a during ontogeny, confining the risk of on-target / off-tumor toxicity. The present invention provides CARs comprising a CD1a-targeting moiety which may be transduced or transformed into T cells. The resultant CARTs are suitable for the treatment of cortical T-ALLs.

The present invention discloses a prediction model for predicting the effect of combined liver cancer treatment based on multimodal MRI radiomics features, as well as its construction method and application, and belongs to the technical field of liver cancer treatment effect prediction. In response to the problem that only some liver cancer patients can benefit from transarterial chemoembolization combined with targeted immunotherapy, the present invention proposes to establish multiple machine learning models before combined treatment through non-invasive multimodal contrast-enhanced MRI radiomics features and clinical factors to predict the tumor treatment response of transarterial chemoembolization combined with molecular targeted immunotherapy, and verify the applicability of the radiomics model using external data sets; in addition, the radiomics model is combined with the clinical model to have better predictive efficiency, and the radiomics features provide incremental predictive value for clinical factors. The present invention can predict the effect of combined treatment for liver cancer patients, thereby selecting a more effective and reasonable treatment plan for different patients before treatment.